These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 21558525)

  • 1. Evaluation of agents to reduce infarct size: it can be quite REVEALing.
    Bhatt DL
    JAMA; 2011 May; 305(18):1908-9. PubMed ID: 21558525
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial.
    Najjar SS; Rao SV; Melloni C; Raman SV; Povsic TJ; Melton L; Barsness GW; Prather K; Heitner JF; Kilaru R; Gruberg L; Hasselblad V; Greenbaum AB; Patel M; Kim RJ; Talan M; Ferrucci L; Longo DL; Lakatta EG; Harrington RA;
    JAMA; 2011 May; 305(18):1863-72. PubMed ID: 21558517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin in patients with ST-segment elevation myocardial infarction.
    Krapf R; Hulter HN
    JAMA; 2011 Aug; 306(7):705; author reply 706. PubMed ID: 21846848
    [No Abstract]   [Full Text] [Related]  

  • 4. Erythropoietin in patients with ST-segment elevation myocardial infarction.
    Chen Y
    JAMA; 2011 Aug; 306(7):705-6; author reply 706. PubMed ID: 21846847
    [No Abstract]   [Full Text] [Related]  

  • 5. Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial.
    Melloni C; Rao SV; Povsic TJ; Melton L; Kim RJ; Kilaru R; Patel MR; Talan M; Ferrucci L; Longo DL; Lakatta EG; Najjar SS; Harrington RA
    Am Heart J; 2010 Nov; 160(5):795-803.e2. PubMed ID: 21095264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epoetin: for better or for worse?
    Lancet Oncol; 2004 Jan; 5(1):1. PubMed ID: 14700601
    [No Abstract]   [Full Text] [Related]  

  • 7. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
    Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
    J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Full results on risks of epoetin emerge 14 years after major dialysis study.
    Epstein K
    BMJ; 2012 May; 344():e3535. PubMed ID: 22619221
    [No Abstract]   [Full Text] [Related]  

  • 9. New oversight put in place for physicians giving anemia drugs to patients with cancer.
    Mitka M
    JAMA; 2010 Apr; 303(14):1355-6. PubMed ID: 20388885
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of epoetin alfa administered every 2 weeks to maintain hemoglobin and quality of life in anemic HIV-infected patients.
    Levine AM; Salvato P; Leitz GJ;
    AIDS Res Hum Retroviruses; 2008 Feb; 24(2):131-9. PubMed ID: 18284320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation of once-weekly and three-times-weekly dosings of epoetin alfa in chemotherapy patients: problems of study design and interpretation.
    Nguyen TV; Trinh GN
    J Clin Oncol; 2002 Feb; 20(3):878. PubMed ID: 11821478
    [No Abstract]   [Full Text] [Related]  

  • 12. Statistical explanations for a community-based study of once-weekly epoetin alfa therapy in patients receiving chemotherapy.
    Gabrilove JL; Sarokhan B; Cremieux P
    J Clin Oncol; 2002 Jun; 20(11):2757-8. PubMed ID: 12039942
    [No Abstract]   [Full Text] [Related]  

  • 13. Guidelines for the use of epoetin in cancer patients: a much-needed step forward in standardizing anemia treatment.
    Henry DH
    Blood; 2003 Oct; 102(7):2697-8. PubMed ID: 14504070
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety concerns for two big anemia drugs.
    Nursing; 2008 Oct; 38(10):12. PubMed ID: 18812980
    [No Abstract]   [Full Text] [Related]  

  • 15. Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?
    Walker RG
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):935-7. PubMed ID: 18579671
    [No Abstract]   [Full Text] [Related]  

  • 16. Anemia in the nursing homes: a complex issue.
    Morley JE
    J Am Med Dir Assoc; 2012 Mar; 13(3):191-4. PubMed ID: 22261540
    [No Abstract]   [Full Text] [Related]  

  • 17. Erythropoietin use.
    Keating M; Faris P; Ritter M
    Orthopedics; 1998 Jan; 21(1):13-4. PubMed ID: 9474627
    [No Abstract]   [Full Text] [Related]  

  • 18. A single-center prospective randomized controlled trial evaluating the safety and efficacy of IntraCoronary Erythropoietin delivery BEfore Reperfusion: gauging infarct size in patients with acute ST-segment elevation myocardial infarction. Study design and rationale of the 'ICEBERG Trial'.
    Suh JW; Yoon YE; Oh IY; Yoon CH; Cho YS; Youn TJ; Chae IH; Choi DJ
    Contemp Clin Trials; 2013 May; 35(1):145-50. PubMed ID: 23506972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Still searching for a new therapeutic strategy for acute myocardial infarction.
    Saito Y
    Circ J; 2010 Nov; 74(11):2290-2. PubMed ID: 20962420
    [No Abstract]   [Full Text] [Related]  

  • 20. Randomized trial on the therapeutic equivalence between Eprex and GerEPO in patients on haemodialysis.
    Goh BL; Ong LM; Sivanandam S; Lim TO; Morad Z;
    Nephrology (Carlton); 2007 Oct; 12(5):431-6. PubMed ID: 17803464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.